

Alpha Emitter Market Size, Share, Trends and Forecast by Type of Radionuclide, Medical Application, End User, and Region, 2026-2034

<https://marketpublishers.com/r/A4D2F4D40C66EN.html>

Date: April 2026

Pages: 144

Price: US\$ 3,999.00 (Single User License)

ID: A4D2F4D40C66EN

Abstracts

The global alpha emitter market size was valued at USD 2,261.0 Million in 2025. Looking forward, IMARC Group estimates the market to reach USD 13,625.1 Million by 2034, exhibiting a CAGR of 21.42% from 2026-2034. North America currently dominates the market, holding a market share of over 43.7% in 2025. Factors such as the increasing focus on targeted cancer treatments, along with the rising number of new nuclear-medicine-based product approvals, are bolstering the alpha emitter market share.

The increased prevalence of cancer and the growing need for targeted alpha therapy (TAT) as an enhanced radiation treatment are driving the worldwide alpha emitter market forward. Alpha emitters, such as actinium-225 and radium-223, provide high linear energy transfer (LET) while causing minimum harm to nearby healthy tissues, making them excellent for precision oncology. Advances in nuclear medicine, together with increased government and private sector investment in radiopharmaceutical research, are accelerating industry growth. Furthermore, the growing use of alpha-emitting isotopes in medical imaging and therapeutic applications, together with regulatory approvals for innovative radiopharmaceuticals, is driving the alpha emitter market demand. The market also benefits from technological advances in isotope manufacturing and the increase of clinical trials testing alpha treatments for various malignancies.

The alpha emitter market in the United States is quickly developing, driven by rising cancer rates and greater awareness of the benefits of targeted alpha treatment. For example, in 2020, there were 274,364 new cancer cases worldwide, highlighting the growing need for improved therapies. Significant expenditures in R&D have fueled this

rise, resulting in advancements in radiopharmaceuticals and alpha-emitting therapeutics. Furthermore, the United States market benefits from a robust healthcare infrastructure and supportive regulatory rules that stimulate the use of cutting-edge therapies. Furthermore, the increasing number of product approvals by regulatory bodies is providing an impetus to the market growth.

ALPHA EMITTER MARKET TRENDS:

Increasing Demand for Targeted Cancer Therapies

The expanding interest in alpha emitters as sources of targeting precisely cancerous cells with lesser destruction to surrounding normal tissue resulting in their diversified applications is impelling the market growth. It has also led to the development of more efficient drugs, mainly because some cancer diseases are unresponsive to drugs with conventional applications, thus giving the patient a better outcome. Cancer cases for NMSC reached a total of 19,976,499 worldwide in 2022 according to the World Cancer Research Fund. For example, in February 2024, the FDA granted a breakthrough device to AlphaMedix, a targeted alpha therapy developed by RadioMedix and Orano Med. This therapy is focused on treating neuroendocrine tumors, which shows advancements in alpha emitter technologies for more effective and targeted cancer treatments.

Expanding Production Capacity of Alpha Emitters

There is a growing need for larger-scale production as more applications for alpha emitters emerge in cancer treatment. Expanding manufacturing infrastructure is critical to ensure a steady supply of these isotopes, thereby meeting the increasing clinical and research demands. For instance, in January 2024, Orano Med began building a new site in Onnain, France, dedicated to producing lead-212 radioligand therapies. This facility will enhance large-scale manufacturing capabilities. Therefore, supporting the alpha emitter market outlook.

Advancements in Manufacturing Technology

The alpha emitter sector is undergoing a revolution due to the development of more scalable and efficient manufacturing technologies, such as cyclotron-based production techniques. The market as a whole is improved by these developments as they lower prices, increase isotope purity, and make alpha particles for medical purposes more widely available and dependable. For example, Actinium Pharmaceuticals started a

strategic project in March 2024 with the goal of manufacturing Actinium-225 using its in-house cyclotron-based technology. This advancement attempts to provide a scalable, economical technique with excellent radiochemical purity in order to meet the increasing need for alpha emitters in targeted cancer treatments.

ALPHA EMITTER INDUSTRY SEGMENTATION:

IMARC Group provides an analysis of the key trends in each segment of the global alpha emitter market, along with forecast at the global, regional, and country levels from 2026-2034. The market has been categorized based on type of radionuclide, medical application, and end user.

Analysis by Type of Radionuclide:

Astatine

Radium

Actinium

Lead

Bismuth

Others

Radium dominates the market with 54.5% shares in 2025. Radium, an alpha emitter, is commonly used in treating metastatic bone cancer. Its targeted approach delivers high-energy alpha particles to cancer cells, minimizing damage to healthy tissues. For example, Xofigo is a well-known treatment utilizing radium-223 for effective cancer management. The growing prevalence of bone metastases, particularly in prostate and breast cancer patients, is driving demand for radium-based therapies. Additionally, increased FDA approvals and ongoing research into expanding radium-223 applications beyond bone cancer are strengthening its market position. Pharmaceutical companies are also investing in optimizing radium formulations for improved efficacy and patient convenience. Moreover, strategic collaborations between healthcare providers and nuclear medicine manufacturers are enhancing accessibility to radium-based treatments, further fueling market growth. With continuous advancements in

radiopharmaceutical development, radium's dominance in the alpha emitter market is expected to persist in the coming years.

Analysis by Medical Application:

Prostate Cancer

Bone Metastasis

Ovarian Cancer

Pancreatic Cancer

Endocrine Tumors

Others

With 36.0% market shares, bone metastasis dominates the alpha emitter industry, owing to the rising frequency of metastatic malignancies, notably prostate, breast, and lung cancer. Alpha-emitting radiopharmaceuticals, such as radium-223 (Xofigo), are commonly used to treat bone metastases because of their ability to precisely target cancer cells while causing minimal damage to adjacent tissues. The increasing need for less invasive, tailored therapy is driving market expansion. Furthermore, advances in nuclear medicine and increased FDA approvals of alpha-emitting medicines are broadening their clinical uses. Growing expenditures in R&D, together with increased patient knowledge and access to radiopharmaceuticals, are projected to maintain bone metastasis applications' dominance in the alpha emitter industry.

Analysis by End User:

Hospitals

Medical Research Institutions

Others

The global alpha emitter market is growing in hospitals due to rising cancer cases and

the increasing adoption of targeted alpha therapy (TAT). Hospitals are incorporating alpha-emitting radiopharmaceuticals such as radium-223 and actinium-225 to enhance cancer treatment, leading to better patient outcomes and fewer side effects.

More investment in medical research institutions spurring alpha emitter application in advanced oncology and other therapeutic areas is driving also the growth of this market. Growing government and private funding support clinical trials, innovations in radiopharmaceuticals, and improved isotope production that accelerates new alpha-based treatments for diseases.

Other end users, including specialty clinics and nuclear medicine centers, contribute to market expansion by offering outpatient alpha therapy solutions. Growing collaborations between pharmaceutical companies and healthcare providers, along with improved regulatory frameworks, are further facilitating the widespread adoption of alpha emitters across diverse healthcare settings.

Regional Analysis:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

As per the alpha emitter analysis report, North America leads the market with 43.7% shares due to strong investments in cancer therapies and advanced medical technologies. Apart from this, the region's focus on targeted alpha therapies for cancer treatment drives demand for alpha emitters like Actinium-225. For example, Actinium Pharmaceuticals in the U.S. is developing innovative alpha therapies for difficult-to-treat cancers. Furthermore, strong healthcare infrastructure and increasing research initiatives continue to propel market growth in North America, thereby ensuring the region remains a prominent player in the market. Additionally, the presence of key pharmaceutical companies, favorable regulatory policies, and increasing clinical trials for novel alpha-emitting radiopharmaceuticals further solidify North America's dominance in this rapidly expanding market.

KEY REGIONAL TAKEAWAYS:

UNITED STATES ALPHA EMITTER MARKET ANALYSIS

The U.S. alpha emitter market is expanding due to the rising incidence of chronic diseases and the increasing need for advanced treatment solutions. According to the U.S. Department of Health and Human Services, approximately 129 million Americans suffer from at least one major chronic condition, including heart disease, cancer, diabetes, obesity, or hypertension. This significant health burden fuels the need for more effective treatments, particularly in the field of cancer care. Alpha-emitting isotopes like actinium-225 and radium-223 are gaining attention for their potential in targeted cancer therapies, offering precision treatment options. The U.S. government's investments in cancer research and a favorable regulatory framework for radiopharmaceuticals further accelerate market growth. Additionally, the demand for diagnostic tools incorporating alpha emitters is on the rise, particularly in personalized medicine to identify and target cancerous tissues. The presence of key industry players and continuous innovation in radiopharmaceuticals strengthens the market's potential. With a growing aging population and rising cancer cases, along with increased funding from both public and private sectors, the U.S. alpha emitter market is poised for substantial growth in the coming years.

EUROPE ALPHA EMITTER MARKET ANALYSIS

The European alpha emitter market is expanding due to the rising incidence of cancer and the increasing demand for targeted treatment options. According to the analysis, the European Union's population on January 1, 2023, was predicted to be 448.8 million, with more than one-fifth (21.3%) aged 65 and more. This aging demographic, combined with rising cancer incidence, is greatly increasing the demand for effective cancer therapies. Alpha-emitting isotopes such as actinium-225, radium-223, and thorium-227 are gaining popularity for their capacity to administer precise, focused therapy, offering patients more effective treatment alternatives. Europe's favorable regulatory environment, with organizations such as the European Medicines Agency (EMA) favoring the approval of novel medicines, is boosting alpha emitter market growth. Furthermore, cooperation among academic institutions, pharmaceutical firms, and healthcare providers are increasing the use of alpha emitters. Europe's strong focus on research and development in radiopharmaceuticals is enabling continued advancements in cancer care, further boosting the market. The region's well-established healthcare system, along with increasing public and private sector funding,

supports the expansion of alpha emitter usage. As these factors converge, Europe is projected to experience steady market expansion, especially in the field of cancer treatment, in the coming years.

ASIA PACIFIC ALPHA EMITTER MARKET ANALYSIS

The Asia Pacific (APAC) alpha emitter market is driven by rising cancer incidence, particularly ovarian cancer, which poses a significant burden in the region. According to reports, while developed countries face a higher risk of ovarian cancer, less developed nations, including China and India, report the highest number of diagnoses, with over 30,000 and 25,000 cases annually, respectively. India also has Asia's highest ovarian cancer mortality rate. This growing disease burden fuels demand for targeted alpha therapy (TAT), particularly for metastatic cancers. Increasing investments in nuclear medicine, advancements in isotope production such as actinium 225 and radium 223, and expanding healthcare infrastructure in China, Japan, and India support market growth. Governments and private entities are enhancing radiopharmaceutical supply chains and regulatory frameworks. Additionally, medical tourism in India and Thailand boosts demand for innovative cancer treatments. Strengthening research collaborations and rising government funding further accelerate the adoption of alpha emitting therapies in APAC.

LATIN AMERICA ALPHA EMITTER MARKET ANALYSIS

In Latin America, the alpha emitter market is gaining momentum due to the increasing prevalence of chronic diseases and a rising demand for advanced healthcare solutions. In Brazil, for instance, approximately 928,000 deaths are attributed to chronic diseases annually, according to reports. The increasing health burden is fueling demand for more effective treatment solutions, including radiopharmaceuticals that utilize alpha emitters. The adoption of precision medicine and advancements in cancer treatments are further boosting market potential. With government initiatives and international partnerships facilitating the development of radiopharmaceuticals, the alpha emitter market in Latin America is poised for growth.

MIDDLE EAST AND AFRICA ALPHA EMITTER MARKET ANALYSIS

The Middle East and Africa (MEA) alpha emitter market is driven by increasing adoption of targeted radionuclide therapies and expanding nuclear medicine infrastructure. Government initiatives to enhance oncology treatment and investments in healthcare facilities further support growth. According to PMC, Arab countries reported 463,675

new cancer cases, accounting for 2.4% of global incidence, highlighting the urgent need for advanced treatment options. Strategic collaborations between international radiopharmaceutical firms and regional providers improve accessibility. Growing awareness and clinical trials evaluating alpha-emitting radiopharmaceuticals fuel innovation.

COMPETITIVE LANDSCAPE:

The global alpha emitter market is highly competitive, with key players focusing on product innovation, strategic partnerships, and geographic expansion to strengthen their market position. Major companies focus on advancing targeted alpha therapy (TAT) for cancer treatment. The market is driven by increasing investments in nuclear medicine and rising clinical research on radiopharmaceuticals. Regulatory approvals and government support for isotope production further shape the competitive landscape. Additionally, partnerships between pharmaceutical firms and research institutions are accelerating R&D efforts. Companies are also expanding their production capabilities to meet growing demand, especially in North America and Europe. However, stringent regulatory frameworks, limited isotope availability, and high production costs pose challenges.

The report provides a comprehensive analysis of the competitive landscape in the alpha emitter market with detailed profiles of all major companies, including:

Actinium Pharmaceuticals, Inc.

Alpha Tau Medical Ltd.

Bayer Corporation

BWXT Medical Ltd

Fusion Pharma

IBA Radiopharma Solutions

NorthStar Medical Radioisotopes, LLC

Orano Group

RadioMedix, Inc.

Telix Pharmaceuticals Limited

TerraPower LLC

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 INTRODUCTION

- 4.1 Overview
- 4.2 Key Industry Trends

5 GLOBAL ALPHA EMITTER MARKET

- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast

6 MARKET BREAKUP BY TYPE OF RADIONUCLIDE

- 6.1 Astatine
 - 6.1.1 Market Trends
 - 6.1.2 Market Forecast
- 6.2 Radium
 - 6.2.1 Market Trends
 - 6.2.2 Market Forecast
- 6.3 Actinium

- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Lead
 - 6.4.1 Market Trends
 - 6.4.2 Market Forecast
- 6.5 Bismuth
 - 6.5.1 Market Trends
 - 6.5.2 Market Forecast
- 6.6 Others
 - 6.6.1 Market Trends
 - 6.6.2 Market Forecast

7 MARKET BREAKUP BY MEDICAL APPLICATION

- 7.1 Prostate Cancer
 - 7.1.1 Market Trends
 - 7.1.2 Market Forecast
- 7.2 Bone Metastasis
 - 7.2.1 Market Trends
 - 7.2.2 Market Forecast
- 7.3 Ovarian Cancer
 - 7.3.1 Market Trends
 - 7.3.2 Market Forecast
- 7.4 Pancreatic Cancer
 - 7.4.1 Market Trends
 - 7.4.2 Market Forecast
- 7.5 Endocrine Tumors
 - 7.5.1 Market Trends
 - 7.5.2 Market Forecast
- 7.6 Others
 - 7.6.1 Market Trends
 - 7.6.2 Market Forecast

8 MARKET BREAKUP BY END USER

- 8.1 Hospitals
 - 8.1.1 Market Trends
 - 8.1.2 Market Forecast
- 8.2 Medical Research Institutions

- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Others
 - 8.3.1 Market Trends
 - 8.3.2 Market Forecast

9 MARKET BREAKUP BY REGION

- 9.1 North America
 - 9.1.1 United States
 - 9.1.1.1 Market Trends
 - 9.1.1.2 Market Forecast
 - 9.1.2 Canada
 - 9.1.2.1 Market Trends
 - 9.1.2.2 Market Forecast
- 9.2 Asia-Pacific
 - 9.2.1 China
 - 9.2.1.1 Market Trends
 - 9.2.1.2 Market Forecast
 - 9.2.2 Japan
 - 9.2.2.1 Market Trends
 - 9.2.2.2 Market Forecast
 - 9.2.3 India
 - 9.2.3.1 Market Trends
 - 9.2.3.2 Market Forecast
 - 9.2.4 South Korea
 - 9.2.4.1 Market Trends
 - 9.2.4.2 Market Forecast
 - 9.2.5 Australia
 - 9.2.5.1 Market Trends
 - 9.2.5.2 Market Forecast
 - 9.2.6 Indonesia
 - 9.2.6.1 Market Trends
 - 9.2.6.2 Market Forecast
 - 9.2.7 Others
 - 9.2.7.1 Market Trends
 - 9.2.7.2 Market Forecast
- 9.3 Europe
 - 9.3.1 Germany

- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
 - 9.3.2.1 Market Trends
 - 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
 - 9.3.3.1 Market Trends
 - 9.3.3.2 Market Forecast
- 9.3.4 Italy
 - 9.3.4.1 Market Trends
 - 9.3.4.2 Market Forecast
- 9.3.5 Spain
 - 9.3.5.1 Market Trends
 - 9.3.5.2 Market Forecast
- 9.3.6 Russia
 - 9.3.6.1 Market Trends
 - 9.3.6.2 Market Forecast
- 9.3.7 Others
 - 9.3.7.1 Market Trends
 - 9.3.7.2 Market Forecast
- 9.4 Latin America
 - 9.4.1 Brazil
 - 9.4.1.1 Market Trends
 - 9.4.1.2 Market Forecast
 - 9.4.2 Mexico
 - 9.4.2.1 Market Trends
 - 9.4.2.2 Market Forecast
 - 9.4.3 Others
 - 9.4.3.1 Market Trends
 - 9.4.3.2 Market Forecast
- 9.5 Middle East and Africa
 - 9.5.1 Market Trends
 - 9.5.2 Market Breakup by Country
 - 9.5.3 Market Forecast

10 SWOT ANALYSIS

- 10.1 Overview
- 10.2 Strengths

10.3 Weaknesses

10.4 Opportunities

10.5 Threats

11 VALUE CHAIN ANALYSIS

12 PORTERS FIVE FORCES ANALYSIS

12.1 Overview

12.2 Bargaining Power of Buyers

12.3 Bargaining Power of Suppliers

12.4 Degree of Competition

12.5 Threat of New Entrants

12.6 Threat of Substitutes

13 PRICE ANALYSIS

14 COMPETITIVE LANDSCAPE

14.1 Market Structure

14.2 Key Players

14.3 Profiles of Key Players

14.3.1 Actinium Pharmaceuticals, Inc.

14.3.1.1 Company Overview

14.3.1.2 Product Portfolio

14.3.1.3 Financials

14.3.2 Alpha Tau Medical Ltd.

14.3.2.1 Company Overview

14.3.2.2 Product Portfolio

14.3.3 Bayer Corporation

14.3.3.1 Company Overview

14.3.3.2 Product Portfolio

14.3.3.3 Financials

14.3.3.4 SWOT Analysis

14.3.4 BWXT Medical Ltd

14.3.4.1 Company Overview

14.3.4.2 Product Portfolio

14.3.4.3 Financials

14.3.4.4 SWOT Analysis

- 14.3.5 Fusion Pharma
 - 14.3.5.1 Company Overview
 - 14.3.5.2 Product Portfolio
 - 14.3.5.3 Financials
- 14.3.6 IBA Radiopharma Solutions
 - 14.3.6.1 Company Overview
 - 14.3.6.2 Product Portfolio
- 14.3.7 NorthStar Medical Radioisotopes, LLC
 - 14.3.7.1 Company Overview
 - 14.3.7.2 Product Portfolio
 - 14.3.7.3 Financials
 - 14.3.7.4 SWOT Analysis
- 14.3.8 Orano Group
 - 14.3.8.1 Company Overview
 - 14.3.8.2 Product Portfolio
 - 14.3.8.3 Financials
 - 14.3.8.4 SWOT Analysis
- 14.3.9 RadioMedix, Inc.
 - 14.3.9.1 Company Overview
 - 14.3.9.2 Product Portfolio
- 14.3.10 Telix Pharmaceuticals Limited
 - 14.3.10.1 Company Overview
 - 14.3.10.2 Product Portfolio
 - 14.3.10.3 Financials
 - 14.3.10.4 SWOT Analysis
- 14.3.11 TerraPower LLC
 - 14.3.11.1 Company Overview
 - 14.3.11.2 Product Portfolio
 - 14.3.11.3 Financials
 - 14.3.11.4 SWOT Analysis

List Of Tables

LIST OF TABLES

Table 1: Global: Alpha Emitter Market: Key Industry Highlights, 2025 and 2034

Table 2: Global: Alpha Emitter Market Forecast: Breakup by Type of Radionuclide (in Million USD), 2026-2034

Table 3: Global: Alpha Emitter Market Forecast: Breakup by Medical Application (in Million USD), 2026-2034

Table 4: Global: Alpha Emitter Market Forecast: Breakup by End User (in Million USD), 2026-2034

Table 5: Global: Alpha Emitter Market Forecast: Breakup by Region (in Million USD), 2026-2034

Table 6: Global: Alpha Emitter Market: Competitive Structure

Table 7: Global: Alpha Emitter Market: Key Players

List Of Figures

LIST OF FIGURES

Figure 1: Global: Alpha Emitter Market: Major Drivers and Challenges

Figure 2: Global: Alpha Emitter Market: Sales Value (in Million USD), 2020-2025

Figure 3: Global: Alpha Emitter Market Forecast: Sales Value (in Million USD), 2026-2034

Figure 4: Global: Alpha Emitter Market: Breakup by Type of Radionuclide (in %), 2025

Figure 5: Global: Alpha Emitter Market: Breakup by Medical Application (in %), 2025

Figure 6: Global: Alpha Emitter Market: Breakup by End User (in %), 2025

Figure 7: Global: Alpha Emitter Market: Breakup by Region (in %), 2025

Figure 8: Global: Alpha Emitter (Astatine) Market: Sales Value (in Million USD), 2020 & 2025

Figure 9: Global: Alpha Emitter (Astatine) Market Forecast: Sales Value (in Million USD), 2026-2034

Figure 10: Global: Alpha Emitter (Radium) Market: Sales Value (in Million USD), 2020 & 2025

Figure 11: Global: Alpha Emitter (Radium) Market Forecast: Sales Value (in Million USD), 2026-2034

Figure 12: Global: Alpha Emitter (Actinium) Market: Sales Value (in Million USD), 2020 & 2025

Figure 13: Global: Alpha Emitter (Actinium) Market Forecast: Sales Value (in Million USD), 2026-2034

Figure 14: Global: Alpha Emitter (Lead) Market: Sales Value (in Million USD), 2020 & 2025

Figure 15: Global: Alpha Emitter (Lead) Market Forecast: Sales Value (in Million USD), 2026-2034

Figure 16: Global: Alpha Emitter (Bismuth) Market: Sales Value (in Million USD), 2020 & 2025

Figure 17: Global: Alpha Emitter (Bismuth) Market Forecast: Sales Value (in Million USD), 2026-2034

Figure 18: Global: Alpha Emitter (Other Type of Radionuclides) Market: Sales Value (in Million USD), 2020 & 2025

Figure 19: Global: Alpha Emitter (Other Type of Radionuclides) Market Forecast: Sales Value (in Million USD), 2026-2034

Figure 20: Global: Alpha Emitter (Prostate Cancer) Market: Sales Value (in Million USD), 2020 & 2025

Figure 21: Global: Alpha Emitter (Prostate Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034

Figure 22: Global: Alpha Emitter (Bone Metastasis) Market: Sales Value (in Million USD), 2020 & 2025

Figure 23: Global: Alpha Emitter (Bone Metastasis) Market Forecast: Sales Value (in Million USD), 2026-2034

Figure 24: Global: Alpha Emitter (Ovarian Cancer) Market: Sales Value (in Million USD), 2020 & 2025

Figure 25: Global: Alpha Emitter (Ovarian Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034

Figure 26: Global: Alpha Emitter (Pancreatic Cancer) Market: Sales Value (in Million USD), 2020 & 2025

Figure 27: Global: Alpha Emitter (Pancreatic Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034

Figure 28: Global: Alpha Emitter (Endocrine Tumors) Market: Sales Value (in Million USD), 2020 & 2025

Figure 29: Global: Alpha Emitter (Endocrine Tumors) Market Forecast: Sales Value (in Million USD), 2026-2034

Figure 30: Global: Alpha Emitter (Other Medical Applications) Market: Sales Value (in Million USD), 2020 & 2025

Figure 31: Global: Alpha Emitter (Other Medical Applications) Market Forecast: Sales Value (in Million USD), 2026-2034

Figure 32: Global: Alpha Emitter (Hospitals) Market: Sales Value (in Million USD), 2020 & 2025

Figure 33: Global: Alpha Emitter (Hospitals) Market Forecast: Sales Value (in Million USD), 2026-2034

Figure 34: Global: Alpha Emitter (Medical Research Institutions) Market: Sales Value (in Million USD), 2020 & 2025

Figure 35: Global: Alpha Emitter (Medical Research Institutions) Market Forecast: Sales Value (in Million USD), 2026-2034

Figure 36: Global: Alpha Emitter (Other End Users) Market: Sales Value (in Million USD), 2020 & 2025

Figure 37: Global: Alpha Emitter (Other End Users) Market Forecast: Sales Value (in Million USD), 2026-2034

Figure 38: North America: Alpha Emitter Market: Sales Value (in Million USD), 2020 & 2025

Figure 39: North America: Alpha Emitter Market Forecast: Sales Value (in Million USD), 2026-2034

Figure 40: United States: Alpha Emitter Market: Sales Value (in Million USD), 2020 & 2025

Figure 41: United States: Alpha Emitter Market Forecast: Sales Value (in Million USD),

2026-2034

Figure 42: Canada: Alpha Emitter Market: Sales Value (in Million USD), 2020 & 2025

Figure 43: Canada: Alpha Emitter Market Forecast: Sales Value (in Million USD),
2026-2034

Figure 44: Asia-Pacific: Alpha Emitter Market: Sales Value (in Million USD), 2020 &
2025

Figure 45: Asia-Pacific: Alpha Emitter Market Forecast: Sales Value (in Million USD),
2026-2034

Figure 46: China: Alpha Emitter Market: Sales Value (in Million USD), 2020 & 2025

Figure 47: China: Alpha Emitter Market Forecast: Sales Value (in Million USD),
2026-2034

Figure 48: Japan: Alpha Emitter Market: Sales Value (in Million USD), 2020 & 2025

Figure 49: Japan: Alpha Emitter Market Forecast: Sales Value (in Million USD),
2026-2034

Figure 50: India: Alpha Emitter Market: Sales Value (in Million USD), 2020 & 2025

Figure 51: India: Alpha Emitter Market Forecast: Sales Value (in Million USD),
2026-2034

Figure 52: South Korea: Alpha Emitter Market: Sales Value (in Million USD), 2020 &
2025

Figure 53: South Korea: Alpha Emitter Market Forecast: Sales Value (in Million USD),
2026-2034

Figure 54: Australia: Alpha Emitter Market: Sales Value (in Million USD), 2020 & 2025

Figure 55: Australia: Alpha Emitter Market Forecast: Sales Value (in Million USD),
2026-2034

Figure 56: Indonesia: Alpha Emitter Market: Sales Value (in Million USD), 2020 & 2025

Figure 57: Indonesia: Alpha Emitter Market Forecast: Sales Value (in Million USD),
2026-2034

Figure 58: Others: Alpha Emitter Market: Sales Value (in Million USD), 2020 & 2025

Figure 59: Others: Alpha Emitter Market Forecast: Sales Value (in Million USD),
2026-2034

Figure 60: Europe: Alpha Emitter Market: Sales Value (in Million USD), 2020 & 2025

Figure 61: Europe: Alpha Emitter Market Forecast: Sales Value (in Million USD),
2026-2034

Figure 62: Germany: Alpha Emitter Market: Sales Value (in Million USD), 2020 & 2025

Figure 63: Germany: Alpha Emitter Market Forecast: Sales Value (in Million USD),
2026-2034

Figure 64: France: Alpha Emitter Market: Sales Value (in Million USD), 2020 & 2025

Figure 65: France: Alpha Emitter Market Forecast: Sales Value (in Million USD),
2026-2034

Figure 66: United Kingdom: Alpha Emitter Market: Sales Value (in Million USD), 2020 & 2025

Figure 67: United Kingdom: Alpha Emitter Market Forecast: Sales Value (in Million USD), 2026-2034

Figure 68: Italy: Alpha Emitter Market: Sales Value (in Million USD), 2020 & 2025

Figure 69: Italy: Alpha Emitter Market Forecast: Sales Value (in Million USD), 2026-2034

Figure 70: Spain: Alpha Emitter Market: Sales Value (in Million USD), 2020 & 2025

Figure 71: Spain: Alpha Emitter Market Forecast: Sales Value (in Million USD), 2026-2034

Figure 72: Russia: Alpha Emitter Market: Sales Value (in Million USD), 2020 & 2025

Figure 73: Russia: Alpha Emitter Market Forecast: Sales Value (in Million USD), 2026-2034

Figure 74: Others: Alpha Emitter Market: Sales Value (in Million USD), 2020 & 2025

Figure 75: Others: Alpha Emitter Market Forecast: Sales Value (in Million USD), 2026-2034

Figure 76: Latin America: Alpha Emitter Market: Sales Value (in Million USD), 2020 & 2025

Figure 77: Latin America: Alpha Emitter Market Forecast: Sales Value (in Million USD), 2026-2034

Figure 78: Brazil: Alpha Emitter Market: Sales Value (in Million USD), 2020 & 2025

Figure 79: Brazil: Alpha Emitter Market Forecast: Sales Value (in Million USD), 2026-2034

Figure 80: Mexico: Alpha Emitter Market: Sales Value (in Million USD), 2020 & 2025

Figure 81: Mexico: Alpha Emitter Market Forecast: Sales Value (in Million USD), 2026-2034

Figure 82: Others: Alpha Emitter Market: Sales Value (in Million USD), 2020 & 2025

Figure 83: Others: Alpha Emitter Market Forecast: Sales Value (in Million USD), 2026-2034

Figure 84: Middle East and Africa: Alpha Emitter Market: Sales Value (in Million USD), 2020 & 2025

Figure 85: Middle East and Africa: Alpha Emitter Market: Breakup by Country (in %), 2025

Figure 86: Middle East and Africa: Alpha Emitter Market Forecast: Sales Value (in Million USD), 2026-2034

Figure 87: Global: Alpha Emitter Industry: SWOT Analysis

Figure 88: Global: Alpha Emitter Industry: Value Chain Analysis

Figure 89: Global: Alpha Emitter Industry: Porter's Five Forces Analysis

I would like to order

Product name: Alpha Emitter Market Size, Share, Trends and Forecast by Type of Radionuclide, Medical Application, End User, and Region, 2026-2034

Product link: <https://marketpublishers.com/r/A4D2F4D40C66EN.html>

Price: US\$ 3,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A4D2F4D40C66EN.html>